Stock CCCC C4 THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News C4 Therapeutics, Inc.

Equities

CCCC

US12529R1077

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-10 pm EDT 		5-day change 1st Jan Change
6.16 USD -9.41% Intraday chart for C4 Therapeutics, Inc. -8.61% +9.03%
May. 09 Stifel Adjusts Price Target on C4 Therapeutics to $14 From $13, Maintains Buy Rating MT
May. 08 C4 Therapeutics Shares Decline as Q1 Revenue Misses Estimates MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Stifel Adjusts Price Target on C4 Therapeutics to $14 From $13, Maintains Buy Rating
MT
C4 Therapeutics Shares Decline as Q1 Revenue Misses Estimates
MT
C4 Therapeutics : Corporate Presentation – May 2024
PU
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
GL
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum
GL
C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024
GL
C4 Therapeutics, Inc. Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024
CI
C4 Therapeutics, Inc.(NasdaqGS:CCCC) added to S&P Biotechnology Select Industry Index
CI
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC Degraders at the American Association for Cancer Research Annual Meeting 2024
AQ
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024
GL
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024
AQ
C4 Therapeutics Collaborating With Germany's Merck KGaA to Advance Research on Targeted Therapies for Cancer
MT
C4 Therapeutics : Corporate Presentation – March 2024
PU
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins
GL
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins
AQ
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA Against Critical Oncogenic Proteins
CI
Morgan Stanley Adjusts Price Target on C4 Therapeutics to $8 From $1, Maintains Equal-Weight Rating
MT
C4 Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CCCC Stock
  4. News C4 Therapeutics, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW